PI3Kα RAS结合域的共价抑制剂会影响由RAS和HER2驱动的瘤生长
Joseph E Klebba1, Nilotpal Roy1, Steffen M Bernard1
1Vividion Therapeutics, 5820 Nancy Ridge Drive, San Diego, CA, USA.
概括
用新型化合物向酸基因酶α (PI3Kα) 的RAS结合域可以抑制小鼠的RAS驱动瘤生长. 这种方法节省了葡萄糖平衡,为治疗依赖RAS的癌症提供了潜在的策略.
科学领域:
- 癌症学
- 分子生物学
- 生物化学
背景情况:
- 由RAS驱动的癌症依赖于RAS-PI3Kα途径的生长.
- 由于影响脂类激酶活性,目前的PI3Kα抑制剂会引起毒性.
- 针对RAS绑定领域 (RBD) 提供了更有选择性的方法.
研究的目的:
- 开发和评估可选择性阻断RAS-PI3Kα相互作用的化合物.
- 在临床前癌症模型中评估这些化合物的疗效.
- 为了确定阻断RAS-PI3Kα是否会影响葡萄糖平衡.
主要方法:
- 在PI3K p110α RBD中开发向氨酸242的共价抑制剂.
- 在携带RAS突变或HER2过度表达瘤的小鼠体内研究.
- 对瘤生长抑制和葡萄糖平衡的评估.
主要成果:
- 这些化合物有效地阻断了PI3Kα的RAS激活.
- 抑制剂在减缓小鼠RAS突变和HER2过度表达瘤的生长方面表现出有效性.
- 没有观察到对胰岛素介导的葡萄糖平衡有不良影响.
结论:
- 选择性抑制RAS-PI3Kα相互作用是对RAS依赖癌症的一种有前途的策略.
- 这种方法避免了与广泛的PI3Kα抑制相关的代谢毒性.
- 使用RAS/ MAPK通路抑制剂的联合治疗可能会提高疗效.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
The JAK-STAT Signaling Pathway
12.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
12.0K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
The Ras Gene
7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.0K
Small GTPases - Ras and Rho
5.2K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
5.2K


